Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of …
M Bernardo, F Rico-Villademoros, C García-Rizo… - Advances in …, 2021 - Springer
Introduction To assess the risk of occurrence and potential determinants of metabolic
disorders in adult patients treated with second-generation antipsychotics (SGAs) under real …
disorders in adult patients treated with second-generation antipsychotics (SGAs) under real …
Antipsychotic-induced alterations in lipid turnover
S Pereira, E Au, SM Agarwal, DC Wright… - Endocrinology, 2023 - academic.oup.com
Schizophrenia is a debilitating psychiatric disorder that is treated with antipsychotics.
However, despite their efficacy, antipsychotics increase the risk of metabolic disorders in a …
However, despite their efficacy, antipsychotics increase the risk of metabolic disorders in a …
The beneficial metabolic actions of prolactin
Y Macotela, X Ruiz-Herrera… - Frontiers in …, 2022 - frontiersin.org
The role of prolactin (PRL) favoring metabolic homeostasis is supported by multiple
preclinical and clinical studies. PRL levels are key to explaining the direction of its actions. In …
preclinical and clinical studies. PRL levels are key to explaining the direction of its actions. In …
Reduction in multiple cardiometabolic risk factors with combined olanzapine/samidorphan compared with olanzapine: post hoc analyses from a 24-week phase 3 …
CU Correll, E Stein, C Graham, L DiPetrillo… - Schizophrenia …, 2023 - academic.oup.com
Abstract Background and Hypotheses Weight gain and adverse cardiometabolic effects
often limit the clinical utility of olanzapine. In ENLIGHTEN-2, combining olanzapine with the …
often limit the clinical utility of olanzapine. In ENLIGHTEN-2, combining olanzapine with the …
Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage …
Abstract Background Second-generation antipsychotics (SGAs) are commonly used to treat
schizophrenia (SCZ), but SGAs may differ in the severity of side effects. Long-term studies …
schizophrenia (SCZ), but SGAs may differ in the severity of side effects. Long-term studies …
Cytokine level changes in schizophrenia patients with and without metabolic syndrome treated with atypical antipsychotics
AS Boiko, IA Mednova, EG Kornetova, VI Gerasimova… - Pharmaceuticals, 2021 - mdpi.com
The present study aims at comparing the change in cytokine levels in schizophrenia patients
treated with atypical antipsychotics, with or without metabolic syndrome (MetS). The study …
treated with atypical antipsychotics, with or without metabolic syndrome (MetS). The study …
An evidence-based review of OLZ/SAM for treatment of adults with schizophrenia or bipolar I disorder
Olanzapine effectively treats schizophrenia and bipolar I disorder (BD-I); however, its use is
limited by the risk of significant weight gain and metabolic effects. OLZ/SAM, a combination …
limited by the risk of significant weight gain and metabolic effects. OLZ/SAM, a combination …
Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients
X Wang, J Huang, J Lu, X Li, H Tang, P Shao - BMC psychiatry, 2024 - Springer
Background To explore the influence of CYP2D6 genetic polymorphism on risperidone
metabolism, thereby affecting risperidone's effects and safeties in patients with chronic …
metabolism, thereby affecting risperidone's effects and safeties in patients with chronic …
The role of the gut microbiome in weight-gain in schizophrenia patients treated with atypical antipsychotics: Evidence based on altered composition and function in a …
X Fang, C Gao, W Wu, X Hu, M Shao, C Zhou, R Cai… - Psychiatry …, 2023 - Elsevier
Objectives We aimed to explore the interconnection between the weight-gain in
schizophrenia patients with atypical antipsychotic treatment and gut microbiome. Methods …
schizophrenia patients with atypical antipsychotic treatment and gut microbiome. Methods …
Cardiovascular risk factors and metabolic syndrome in patients treated with long-acting injectables antipsychotics: a retrospective study
V De Carlo, B Grancini, N Cassina… - International Clinical …, 2023 - journals.lww.com
The present cross-sectional, retrospective study aimed to assess the prevalence of
cardiovascular disease (CVD) risk factors and metabolic syndrome in a sample of …
cardiovascular disease (CVD) risk factors and metabolic syndrome in a sample of …